Skip to main content

Table 3 Predictors of parasite reduction ratio ≥ 10 000 two days after initiation of artemisinin-based combination therapies in acutely malarious young children

From: Parasite reduction ratio one day after initiation of artemisinin-based combination therapies and its relationship with parasite clearance time in acutely malarious children

Variable

Total No.

No. with PRRD2 ≥ 10 000

OR (95% CI)

P value

aOR (95% CI)

P value

Gender

 Female

424

202

1

   

 Male

495

240

1.0 (0.8–1.3)

0.85

–

–

Age (month)

  ≤ 30

284

121

1

 

1

 

  > 30

629

320

1.4 (1.1–1.9)

0.02

1.4 (1.0–1.9)

0.03

Duration of illness (days)

  ≤ 2

269

163

1

   

  > 2

334

194

1.3 (0.8–2.0)

0.59

–

–

Haematocrit at presentation (%)

  < 31

465

201

1

 

1

 

  ≥ 31

434

236

1.6 (1.2–2.0)

0.001

1.5 (1.1–1.9)

0.01

Haematocrit on day 1 (%)

  < 30

407

123

1

   

  ≥ 30

483

226

0.8 (0.6–1.0)

0.11

–

–

History of fever before treatment

 Absent

170

75

1

   

 Present

749

367

1.2 (0.9–1.7)

0.29

–

–

Temperature at presentation (°C)

  ≤ 37.4

349

125

1

 

1

 

  > 37.4

570

317

2.2 (1.7–3.0)

< 0.0001

2.0 (1.5–2.7)

< 0.0001

Fever on day 1*

 Absent

797

394

1

   

 Present

103

47

0.9 (0.6–1.3)

0.53

–

–

Enrolment Parasitaemia

  ≤ 105

823

380

1

 

1

 

  > 105

96

62

2.1 (1.4–3.3)

< 0.0001

1.9 (1.2–3)

0.01

PRRD1

  ≤ 103

501

205

1

 

1

 

  > 103

418

237

1.9 (1.5–2.5)

< 0.0001

2.1 (1.6–2.7)

< 0.0001

Gametocytaemia

 Present

48

10

1

 

1

 

 Absent

871

432

3.7 (1.8–7.6)

< 0.0001

2.4 (1.1–5.0)

0.02

Drug treatment

 AL

303

141

1

   

 AA

295

144

1.1 (0.8–1.5)

0.64

–

–

 DHP

321

157

1.1 (0.8–1.5)

0.61

–

–

  1. PRRD1 Parasite reduction ratio 1 day post-treatment initiation, PRRD2 Parasite reduction ratio 2 days post-treatment initiation, AL Artemether-lumefantrine, AA Artesunate-amodiaquine, DHP Ddihydroartemisinin-piperaquine, CI Confidence interval, OR Odd ratio, aOR Adjusted odd ratio
  2. *Fever 1 day post-treatment initiation